cyc 202 has been researched along with Cell Transformation, Neoplastic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akli, S; Bui, T; Keyomarsi, K; Meijer, L; Van Pelt, CS | 1 |
| Akli, S; Duong, MT; Hunt, KK; Keyomarsi, K; Liu, W; Lu, Y; Mills, GB; Wei, C; Wingate, HF; Yi, M | 1 |
| David-Pfeuty, T | 1 |
3 other study(ies) available for cyc 202 and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E.
Topics: Animals; Cell Transformation, Neoplastic; Cyclin E; Cyclin-Dependent Kinase 2; Female; Gene Silencing; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Knockout; Protein Isoforms; Protein Kinase Inhibitors; Purines; Roscovitine | 2011 |
LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients.
Topics: Acinar Cells; Animals; Benzenesulfonates; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cyclin E; Cyclin-Dependent Kinase 2; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Mammary Glands, Animal; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Protein Isoforms; Proto-Oncogene Proteins B-raf; Purines; Pyridines; Retrospective Studies; Roscovitine; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases | 2012 |
Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
Topics: Blotting, Western; Breast Neoplasms; Carcinoma; CDC2-CDC28 Kinases; Cell Cycle; Cell Death; Cell Line; Cell Line, Transformed; Cell Nucleolus; Cell Nucleus; Cell Transformation, Neoplastic; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme Inhibitors; G1 Phase; Humans; Inhibitory Concentration 50; Kinetin; Mitomycin; Nucleic Acid Synthesis Inhibitors; Nucleolin; Phosphoproteins; Protein Serine-Threonine Kinases; Purines; RNA-Binding Proteins; Roscovitine; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |